A detailed history of Claret Asset Management Corp transactions in Exelixis, Inc. stock. As of the latest transaction made, Claret Asset Management Corp holds 8,949 shares of EXEL stock, worth $326,191. This represents 0.04% of its overall portfolio holdings.

Number of Shares
8,949
Previous 8,902 0.53%
Holding current value
$326,191
Previous $200,000 16.0%
% of portfolio
0.04%
Previous 0.04%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$21.96 - $27.6 $1,032 - $1,297
47 Added 0.53%
8,949 $232,000
Q2 2024

Aug 14, 2024

BUY
$20.34 - $23.73 $181,066 - $211,244
8,902 New
8,902 $200,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.7B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Claret Asset Management Corp Portfolio

Follow Claret Asset Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Claret Asset Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on Claret Asset Management Corp with notifications on news.